Zacks: Brokerages Set $5.50 Target Price for AEterna Zentaris Inc. (NASDAQ:AEZS)

AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price objective of $5.50 for the company and are predicting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 83 out of 256 based on the ratings given to its competitors.

Several equities research analysts recently commented on the stock. ValuEngine cut shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a research report on Tuesday, June 11th. TheStreet cut shares of AEterna Zentaris from a “c-” rating to a “d” rating in a research report on Thursday, June 13th.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning bought a new stake in AEterna Zentaris in the 2nd quarter valued at $30,000. Jane Street Group LLC bought a new stake in AEterna Zentaris in the 4th quarter valued at $30,000. Virtu Financial LLC bought a new stake in AEterna Zentaris in the 1st quarter valued at $179,000. Acadian Asset Management LLC lifted its position in AEterna Zentaris by 271.2% during the 1st quarter. Acadian Asset Management LLC now owns 167,222 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 122,173 shares in the last quarter. Finally, AJO LP bought a new stake in AEterna Zentaris during the 1st quarter worth about $1,031,000. 13.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of AEZS stock traded up $0.25 on Tuesday, hitting $2.49. The stock had a trading volume of 46,236 shares, compared to its average volume of 227,575. AEterna Zentaris has a twelve month low of $1.29 and a twelve month high of $5.57. The firm has a market cap of $39.29 million, a price-to-earnings ratio of 9.96 and a beta of 1.26. The company has a fifty day simple moving average of $2.60.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

See Also: Why do corrections happen?

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.